Skip to main content
Schott Pharma logo

Schott Pharma — Investor Relations & Filings

Ticker · 1SXP ISIN · DE000A3ENQ51 LEI · 529900TU48UE99NHEY88 F Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-01-13 Declaration of Voting R…
Country DE Germany
Listing F 1SXP

About Schott Pharma

https://www.schott-pharma.com/en

Schott Pharma is a developer and manufacturer of drug containment solutions and delivery systems for injectable drugs. Serving the pharmaceutical and biotech industries, its portfolio includes prefillable syringes, cartridges, vials, and ampoules. The company provides scientifically proven products designed for the safe storage and administration of medications. Beyond individual components, Schott Pharma offers complete, compatible systems and a range of services, including analytical, development, fill-and-finish, and regulatory support. This integrated approach supports clients from clinical trials through to commercialization, ensuring compatibility across the entire pharma value chain.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It details changes in voting rights percentages (crossing thresholds) held by a shareholder (T. Rowe Price Group, Inc.) in the issuer (SCHOTT Pharma AG & Co. KGaA). This specific type of regulatory disclosure regarding changes in significant share ownership directly maps to the 'Major Shareholding Notification' category.
2025-01-13 English
SCHOTT Pharma 2024 Präsentation (englisch)
Investor Presentation Classification · 1% confidence The document is titled "FY 2024 Results presentation" and features sections like "A year of success," "Strong performance: All FY 2024 targets achieved," "Financial Update," and "Financial guidance for FY 2025." It includes key financial figures for Q4 2024 and FY 2024, presented by the CEO and CFO. This structure is characteristic of an Investor Presentation (IP) used to discuss recent performance and future outlook, often following an Earnings Release (ER). Since it is a detailed presentation format, IP is the most appropriate classification over ER (which is usually just the initial press release highlights). It is not a full Annual Report (10-K) or a formal Interim Report (IR), but rather a presentation summarizing those results.
2024-12-17 English
Sustainability Report 2023/2024
Environmental & Social Information Classification · 1% confidence The document is explicitly titled 'SUSIampability Report 2023/2024' and contains extensive sections detailing the company's performance, strategy, and progress on environmental, social, and governance (ESG) factors, such as CO2 emissions, waste management, diversity, and occupational health and safety. The 'About this report' section confirms it reports on sustainability strategy and progress in accordance with GRI standards. This content directly aligns with the definition of an Environmental & Social Information report (ESG/Sustainability Report). Although it mentions an 'Annual Report' separately, this document itself is the dedicated sustainability disclosure.
2024-12-17 English
SCHOTT Pharma with strong growth and record margin after solid year-end finish
Earnings Release Classification · 1% confidence The document is a news release dated December 12, 2024, announcing financial results for the fiscal year 2024 (FY 2024) and Q4 2024. It explicitly mentions 'Key word(s): Annual Report/Annual Results' and provides key performance indicators (Revenue, EBITDA margin, EPS) and outlook for FY 2025. This structure—a press release summarizing the full year's performance immediately following the close of the fiscal year—is characteristic of an Earnings Release (ER). While it discusses the 'Annual Report' results, the document itself is the initial public announcement of those results, not the comprehensive 10-K filing. It is too detailed for just a Report Publication Announcement (RPA) and contains the core financial highlights. FY 2024
2024-12-13 English
SCHOTT Pharma with strong growth and record margin after solid year-end finish
Earnings Release Classification · 1% confidence The document is a news release dated December 12, 2024, announcing financial results for the fiscal year 2024 (FY 2024) and Q4 2024. It explicitly mentions 'Key word(s): Annual Report/Annual Results' and provides key performance indicators (Revenue, EBITDA margin, EPS) and outlook for FY 2025. This structure—a press release summarizing the full year's performance immediately following the close of the fiscal year—is characteristic of an Earnings Release (ER). While it discusses the 'Annual Report' results, the document itself is the initial public announcement of those results, not the comprehensive 10-K filing. It is too detailed for just a Report Publication Announcement (RPA) and contains the core financial highlights. FY 2024
2024-12-12 English
Sustainability Report 2023/2024
Environmental & Social Information Classification · 1% confidence The document is explicitly titled 'Sustainability Report 2023/2024' for SCHOTT Pharma. It details the company's sustainability strategy, environmental impact (GHG emissions, waste, water), social responsibility (employees, product quality), and governance practices. It follows GRI standards and includes a GRI index. This aligns perfectly with the definition of an Environmental & Social Information (SR) report.
2024-12-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.